Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab induction in locally advanced NSCLC
NCT04287894Phase 1Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2018
- Primary completion
- Nov 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Started Dec 2018; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04287894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04287894.